Abstract:Objective: To develop a new cationic nanoemulsion (NE) for ophthalmic delivery of indomethacin (IND) to improve the permeability and retention time of formulations, thereby improving the drug's ocular bioavailability. Methods: Based on the solubility profile of indomethacin in various solvents, captex 8000 was selected as oil phase, span 20 as a surfactant and tween 20 as co-surfactant to construct pseudo ternary phase diagrams and nanoemulsion region was recognized. Sonication was used as the method of NE preparation. Optimization was done using 32 factorial designs by considering the oil and the ratio of surfactant to co-surfactant (Smix) quantities as independent variables and evaluated for different physicochemical properties. Ex vivo transcorneal permeability was studied using bovine cornea, the In vivo drug pharmacokinetics of optimized NE and marketed formulation were assessed in rabbit aqueous humor and also in plasma. Results: The mean globule size, zeta potential, viscosity, refractive index, pH, surface tension and the osmolarity values for the prepared indomethacin nanoemulsions (IND-NEs) were found between 129.8±1.1 to 191.4±1.6 nm,+13.20±4.6 to+23.45±4.82, 15.3±0.1 to 32.7±0.0 mPas, 1.346±0.007 to 1.386±0.005, 5.5±0.4 to 6.9±0.9, 32.0±2.6 to 52.3±3.4 mN/m and 303-395 mOsm/l respectively and all these values found to be falling under the recommended values for ophthalmic use. From the In vitro release studies, it was found that the IND-NEs exhibited sustained drug release with 67.91±2.01 to 95.90±1.93 % drug release at 24h when compared to the drug solution which showed 99.81±5.21 % drug release within 2h. The Ex vivo drug permeation through the corneal membrane at 4h from the optimized NE and drug solution was found to be 524±1.5 μg/cm2 and 175±2.6 μg/cm2 respectively. Further, the optimized NE was found to be nonirritant with the lowest ocular irritation potential (Iirr) of 1 towards the rabbit's eyes. The area under the drug concentration vs. time curve for 24h (AUC (0–24h)) for optimized NE and the marketed formulation was found to be 1514.99 ng/ml/h and 974.14 ng/ml/h in aqueous humour; 2266.83 ng/ml/h and 778.15 ng/ml/h in plasma respectively. Conclusion: Due to its improved corneal absorption and prolonged drug release along with less systemic absorption, the optimized NE offers an effective postoperative treatment with increased ocular bioavailability and improved patient compliance with a decrease in the number of installations per day and a decrease or disappearance of systemic side effects of IND.

DEVELOPMENT AND OPTIMIZATION OF INDOMETHACIN NANOSUSPENSIONS USING DESIGN OF EXPERIMENT APPROACHES

Strategizing Spray Drying Process Optimization for the Manufacture of Redispersible Indomethacin Nanoparticles Using Quality-by-Design Principles

Preparation and characterization of soluplus-based nanosuspension for dissolution enhancement of indomethacin using ultrasonic assisted precipitation method for formulation and Box-Behnken design for optimization

"Optimizing Pharmaceutical Formulations: Advancements in Nanosuspension Pre-Formulation to Enhance Solubility and Bioavailability of Active Agents"

DEVELOPMENT OF NANOEMULSION TO IMPROVE THE OCULAR BIOAVAILABILITY AND PATIENT COMPLIANCE IN POSTOPERATIVE TREATMENT USING INDOMETHACIN

Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation

Method Development for Simultaneously Determining Indomethacin and Nicotinamide in New Combination in Oral Dosage Formulations and Co-Amorphous Systems Using Three UV Spectrophotometric Techniques

A Design of Experiment (DoE) based approach for development and optimization of nanosuspensions of telmisartan, a BCS class II antihypertensive drug

Optimization of indomethacin loaded hollow mesoporous silica nanoparticles by response surface method

24 Factorial Design Formulation Optimization and in Vitro Characterization of Desloratadine Nanosuspension Prepared Using Antisolvent Precipitation.

Design and in Vitro Evaluation of Self-Assembled Indometacin Prodrug Nanoparticles for Sustained/controlled Release and Reduced Normal Cell Toxicity

Preparation and optimization of superabsorbent hydrogel micromatrices based on poly(acrylic acid), partly sodium salt-g-poly(ethylene oxide) for modified release of indomethacin

Application of Plakett-Burman Screening Design in Optimization of Process Parameters for Formulation of Canaglifozin Nanosuspension

Combination of Dissolving Microneedles with Nanosuspension and Co-Grinding for Transdermal Delivery of Ketoprofen

Study on the Preparation and in Vitro Percutaneous Absorption of Indomethacin Eutectic-Nanoemulsion

FORMULATION AND IN VITRO EVALUATION OF AZILSARTAN MEDOXOMIL NANOSUSPENSION

Preparation and Quality Control of Rapid-disintegrating Oral Tablets of Indometacin

Preparation of Nimodipine Nanosuspension by Wet Milling

Preparation of Indomethacin Sustained-release Pellets by Extrusion-spheronization Method

The Effects of Different Solubilizing Agents on the Transport and Pharmacokinetic Profiles of Indocmethacin: In vitro and in vivo Approach